Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer???s Disease in the Health Care Systems of Different Countries
- 1 January 2004
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 21 (10) , 677-686
- https://doi.org/10.2165/00002512-200421100-00005
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 MonthsDementia and Geriatric Cognitive Disorders, 2003
- Assessment of Health Economics in Alzheimer??s Disease (AHEAD)PharmacoEconomics, 2002
- The Cost of Treatment of Alzheimer??s Disease in The NetherlandsPharmacoEconomics, 2001
- The Epidemic of Alzheimer??s DiseasePharmacoEconomics, 2000
- Worldwide Prevalence and Incidence of DementiaDrugs & Aging, 1999
- Costs of dementia and dementia care: a reviewInternational Journal of Geriatric Psychiatry, 1997
- Group-Living Care: An Alternative for the Demented ElderlyDementia and Geriatric Cognitive Disorders, 1997
- Cost-Utility Analysis of Group Living in Dementia CareInternational Journal of Technology Assessment in Health Care, 1995
- Patterns of Caring for People with Dementia in Canada The Canadian Study of Health and AgingCanadian Journal on Aging / La Revue canadienne du vieillissement, 1994
- DEMENTIA IN OLD AGE AND THE NEED FOR SERVICESAge and Ageing, 1983